Doug Williams takes on CAR T cell access as TriArm CEO

Cross-border infrastructure and a platform technology that supports broader CAR T cell access models have drawn biotech veteran Doug Williams to a new role as CEO of TriArm Therapeutics.

Williams was EVP and president of R&D at another cell therapy company, Sana Biotechnology Inc. (NASDAQ:SANA), until his recent departure, announced in April. He was co-founder and CEO of exosome company Codiak Biosciences Inc. (NASDAQ:CDAK) before joining Sana, and previously served as EVP of R&D at Biogen Inc. (NASDAQ:BIIB)...